198 related articles for article (PubMed ID: 18852140)
1. Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines.
Galmarini CM; Warren G; Kohli E; Zeman A; Mitin A; Vinogradov SV
Mol Cancer Ther; 2008 Oct; 7(10):3373-80. PubMed ID: 18852140
[TBL] [Abstract][Full Text] [Related]
2. Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs.
Galmarini CM; Warren G; Senanayake MT; Vinogradov SV
Int J Pharm; 2010 Aug; 395(1-2):281-9. PubMed ID: 20580798
[TBL] [Abstract][Full Text] [Related]
3. Comparison of nanogel drug carriers and their formulations with nucleoside 5'-triphosphates.
Vinogradov SV; Kohli E; Zeman AD
Pharm Res; 2006 May; 23(5):920-30. PubMed ID: 16715382
[TBL] [Abstract][Full Text] [Related]
4. Effects of gemcitabine and araC on in vitro DNA synthesis mediated by the human breast cell DNA synthesome.
Jiang HY; Hickey RJ; Abdel-Aziz W; Malkas LH
Cancer Chemother Pharmacol; 2000; 45(4):320-8. PubMed ID: 10755321
[TBL] [Abstract][Full Text] [Related]
5. Formulations of biodegradable Nanogel carriers with 5'-triphosphates of nucleoside analogs that display a reduced cytotoxicity and enhanced drug activity.
Kohli E; Han HY; Zeman AD; Vinogradov SV
J Control Release; 2007 Aug; 121(1-2):19-27. PubMed ID: 17509713
[TBL] [Abstract][Full Text] [Related]
6. Cross-linked polymeric nanogel formulations of 5'-triphosphates of nucleoside analogues: role of the cellular membrane in drug release.
Vinogradov SV; Kohli E; Zeman AD
Mol Pharm; 2005; 2(6):449-61. PubMed ID: 16323952
[TBL] [Abstract][Full Text] [Related]
7. Polyplex Nanogel formulations for drug delivery of cytotoxic nucleoside analogs.
Vinogradov SV; Zeman AD; Batrakova EV; Kabanov AV
J Control Release; 2005 Sep; 107(1):143-57. PubMed ID: 16039001
[TBL] [Abstract][Full Text] [Related]
8. Application of activated nucleoside analogs for the treatment of drug-resistant tumors by oral delivery of nanogel-drug conjugates.
Senanayake TH; Warren G; Wei X; Vinogradov SV
J Control Release; 2013 Apr; 167(2):200-9. PubMed ID: 23385032
[TBL] [Abstract][Full Text] [Related]
9. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
[TBL] [Abstract][Full Text] [Related]
10. Novel anticancer polymeric conjugates of activated nucleoside analogues.
Senanayake TH; Warren G; Vinogradov SV
Bioconjug Chem; 2011 Oct; 22(10):1983-93. PubMed ID: 21863885
[TBL] [Abstract][Full Text] [Related]
11. Polymerization of the triphosphates of AraC, 2',2'-difluorodeoxycytidine (dFdC) and OSI-7836 (T-araC) by human DNA polymerase alpha and DNA primase.
Richardson KA; Vega TP; Richardson FC; Moore CL; Rohloff JC; Tomkinson B; Bendele RA; Kuchta RD
Biochem Pharmacol; 2004 Dec; 68(12):2337-46. PubMed ID: 15548380
[TBL] [Abstract][Full Text] [Related]
12. Nano-NRTIs: efficient inhibitors of HIV type-1 in macrophages with a reduced mitochondrial toxicity.
Vinogradov SV; Poluektova LY; Makarov E; Gerson T; Senanayake MT
Antivir Chem Chemother; 2010 Oct; 21(1):1-14. PubMed ID: 21045256
[TBL] [Abstract][Full Text] [Related]
13. Polymeric nanogel formulations of nucleoside analogs.
Vinogradov SV
Expert Opin Drug Deliv; 2007 Jan; 4(1):5-17. PubMed ID: 17184158
[TBL] [Abstract][Full Text] [Related]
14. A new, simple method for quantifying gemcitabine triphosphate in cancer cells using isocratic high-performance liquid chromatography.
Nishi R; Yamauchi T; Ueda T
Cancer Sci; 2006 Nov; 97(11):1274-8. PubMed ID: 17034368
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.
Bergman AM; Adema AD; Balzarini J; Bruheim S; Fichtner I; Noordhuis P; Fodstad O; Myhren F; Sandvold ML; Hendriks HR; Peters GJ
Invest New Drugs; 2011 Jun; 29(3):456-66. PubMed ID: 20066470
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.
Heinemann V; Hertel LW; Grindey GB; Plunkett W
Cancer Res; 1988 Jul; 48(14):4024-31. PubMed ID: 3383195
[TBL] [Abstract][Full Text] [Related]
17. Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel.
Adema AD; Laan AC; Myhren F; Fichtner I; Verheul HM; Sandvold ML; Peters GJ
Int J Oncol; 2010 Jan; 36(1):285-94. PubMed ID: 19956857
[TBL] [Abstract][Full Text] [Related]
18. Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
Bergman AM; Pinedo HM; Jongsma AP; Brouwer M; Ruiz van Haperen VW; Veerman G; Leyva A; Eriksson S; Peters GJ
Biochem Pharmacol; 1999 Feb; 57(4):397-406. PubMed ID: 9933028
[TBL] [Abstract][Full Text] [Related]
19. pH responsive biodegradable nanogels for sustained release of bleomycin.
Sahu P; Kashaw SK; Kushwah V; Sau S; Jain S; Iyer AK
Bioorg Med Chem; 2017 Sep; 25(17):4595-4613. PubMed ID: 28734664
[TBL] [Abstract][Full Text] [Related]
20. Unlocking a caged lysosomal protein from a polymeric nanogel with a pH trigger.
Molla MR; Marcinko T; Prasad P; Deming D; Garman SC; Thayumanavan S
Biomacromolecules; 2014 Nov; 15(11):4046-53. PubMed ID: 25291086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
